John Nemunaitis

26PUBLICATIONS
41CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Human impacts of climate change and human adaptationCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jan 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Robert L Coleman, Rodney Rocconi, Bradley J Monk

|Mar 24, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncology.

Susan Morand, Lauren Rager, Daniel Craig

|Aug 05, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.

John Nemunaitis, Laura Stanbery, Adam Walter

|Apr 23, 2024
Regulatory role of CD39 and CD73 in tumor immunity.

Nicole Kaplinsky, Kada Williams, Dean Watkins

|Mar 28, 2024
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.

Morgan Bailey, Susan Morand, Rachel Royfman

|Dec 09, 2023
Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.

John Nemunaitis, Laura Stanbery, David Willoughby

Pageof 5

Frequent Collaborators

2 joint publications

Daniel J Craig

2 joint publications

Ernest Bognar

2 joint publications

Staci Horvath

2 joint publications

Phylicia Aaron